|
1
|
Nutt JG and Wooten GF: Clinical practice.
Diagnosis and initial management of Parkinson's disease. N Engl J
Med. 353:1021–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Calabresi P, Giacomini P, Centonze D and
Bernardi G: Levodopa-induced dyskinesia: A pathological form of
striatal synaptic plasticity? Ann Neurol. 47:S60–S68.
2000.PubMed/NCBI
|
|
3
|
Baier CJ, Pallarés ME, Adrover E, Katunar
MR, Raisman-Vozari R and Antonelli MC: Intrastriatal 6-OHDA lesion
differentially affects dopaminergic neurons in the ventral
tegmental area of prenatally stressed rats. Neurotox Res.
26:274–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ren J, Zhang Y, Jin H, Yu J, Zhou Y, Wu F
and Zhang W: Novel inhibitors of human DOPA decarboxylase extracted
from Euonymus glabra Roxb. ACS Chem Biol. 9:897–903. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bolea I, Colivicchi MA, Ballini C,
Marco-Contelles J, Tipton KF, Unzeta M and Della Corte L:
Neuroprotective effects of the MAO-B inhibitor, PF9601N, in an
in vivo model of excitotoxicity. CNS Neurosci Ther.
20:641–650. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Onzawa Y, Kimura Y, Uzuhashi K, Shirasuna
M, Hirosawa T, Taogoshi T and Kihira K: Effects of
3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on
locomotor activity and dopamine turnover in rats. Biol Pharm Bull.
35:1244–1248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Noack C, Schroeder C, Heusser K and Lipp
A: Cardiovascular effects of levodopa in Parkinson's disease.
Parkinsonism Relat Disord. 20:815–818. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hong JY, Oh JS, Lee I, Sunwoo MK, Ham JH,
Lee JE, Sohn YH, Kim JS and Lee PH: Presynaptic dopamine depletion
predicts levodopa-induced dyskinesia in de novo Parkinson
disease. Neurology. 82:1597–1604. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alachkar A, Brotchie JM and Jones OT:
Locomotor response to L-DOPA in reserpine-treated rats following
central inhibition of aromatic L-amino acid decarboxylase: Further
evidence for non-dopaminergic actions of L-DOPA and its
metabolites. Neurosci Res. 68:44–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu HB and Fang YQ: Pharmacokinetics of
beta-asarone in rats. Yao Xue Xue Bao. 39:836–838. 2004.(In
Chinese). PubMed/NCBI
|
|
11
|
Huang L, Deng M, Zhang S, Fang Y and Li L:
Coadministration of β-asarone and levodopa increases dopamine in
rat brain by accelerating transformation of levodopa: A different
mechanism from Madopar. Clin Exp Pharmacol Physiol. 41:685–690.
2014.PubMed/NCBI
|
|
12
|
Veloso A, Fernández R, Astigarraga E,
Barreda-Gómez G, Manuel I, Giralt MT, Ferrer I, Ochoa B,
Rodríguez-Puertas R and Fernández JA: Distribution of lipids in
human brain. Anal Bioanal Chem. 401:89–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu L and Fang YQ: Analysis of the
distribution of β-asarone in rat hippocampus, brainstem, cortex and
cerebellum with GC-MS. J Med Plants Res. 9:1728–1734. 2011.
|
|
14
|
Fang YQ, Shi C, Liu L and Fang RM:
Analysis of transformation and excretion of β-asarone in rabbits
with GC-MS. Eur J Drug Metab Pharmacokinet. 37:187–190. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang S, Gui XH, Xue ZF, Huang LP, Fang
RM, Ke XH, Li L and Fang YQ: Dynamic of neurochemical alterations
in striatum, hippocampus and cortex after the 6-OHDA mesostriatal
lesion. Int J Dev Neurosci. 36:32–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei G, Chen YB, Chen DF, Lai XP, Liu DH,
Deng RD, Zhou JH, Zhang SX, Li YW, Lii H, et al: β-Asarone inhibits
neuronal apoptosis via the CaMKII/CREB/Bcl-2 signaling pathway in
an in vitro model and AβPP/PS1 mice. J Alzheimers Dis. 33:863–880.
2013.PubMed/NCBI
|
|
17
|
Takáts A, Nagy H, Radics P, Tóth A and
Tamás G: Treatment possibilities in advanced Parkinson's disease.
Ideggyogy Sz. 66:365–371. 2013.(In Hungarian). PubMed/NCBI
|
|
18
|
Lazzara CA, Riley RR, Rane A, Andersen JK
and Kim YH: The combination of lithium and I-Dopa/Carbidopa reduces
MPTP-induced abnormal involuntary movements (AIMs) via calpain-1
inhibition in a mouse model: Relevance for Parkinsons disease
therapy. Brain Res. June 26–2015.(epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu T, Liu J, Zhang H, Hallett M, Zheng Z
and Chan P: Attention to automatic movements in Parkinson's
disease: Modified automatic mode in the striatum. Cereb Cortex.
June 12–2014.(epub ahead of print). View Article : Google Scholar
|
